INFINITY PHARMA
ActiveSummary
INFINITY PHARMA has been active since 1976 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €16.4m and a net result of -€231,419. Equity fluctuates too strongly from year to year to read a trend from it. Its solvency ranks better than 91% of 6,172 sector peers (NACE 46, financial year 2025). The computed 12-month bankruptcy probability is 0.3% (very low).
Overview
Official details
Source: KBO- Status
- Active since 08-12-1976 Normal situation
- Activity
- Wholesale of pharmaceutical and medical goods NACE 46460
- Joint committees
- 207 Paritair Comité voor de bedienden uit de scheikundige nijverheid
- 116 Paritair Comité voor de scheikundige nijverheid · annual accounts 2025
- Establishment unit
- 2.013.193.230 9810 Nazareth-De Pinte, since 31-03-1992
- Financial year end
- 31 December
- Peppol
- Reachable since 01-10-2025
Board and ownership
Shareholders
- Fagron NVconsolidatesannual accounts 2025
- Holdings
- Shares in 3 companies including FAGRON BELGIUM and FAGRON COMPOUNDING SERVICES
Financial position
- Bankruptcy probabilitywithin 12 months
- 0.3%
Annual accounts 2025
- Turnover
- €10.7m
- ▲ 0.6%
- Loss
- €231,419
- ▼ 71.9%
- Equity
- €16.4m
- ▲ 29.8%
- Total assets
- €18.8m
- ▲ 17.8%
- Employees on 31-12-2025
- 13
- ▼ 13.3%
Score breakdownraises riskLiquidity: current ratio 1.44, cash €688,3361 of the last 3 accounts latelowers riskFounded in 1976Equity €16.4m (87.2% of total assets)Show the evidence
Checked score
Score 2025
86
/ 100
Excellent
Probability in this band: under 0.55%
Financially stronger than 61% of small companies in wholesale trade (NACE 46)
Financial strength · tick: 2024
Strong
Solvency
100=
equity 87.2% of total assets
Liquidity
53+9
short-term debt 12.8% · cash 3.7%
Profitability
20+10
return on assets -1.2%
Bankruptcy probability within 12 months
0.3%
Very low
0%0.5%1.5%4%10%≥ 25%
About 3 in 1,000 comparable companies go bankrupt within 12 months (an estimate).
Last 24 months
12-2024: 3.3%
01-2025: 3.3%● unchanged vs 12-2024
02-2025: 3.2%▼ -0.1 percentage points vs 01-2025
03-2025: 3.3%▲ +0.1 percentage points vs 02-2025
04-2025: 3.3%● unchanged vs 03-2025
05-2025: 3.3%● unchanged vs 04-2025
06-2025: 3.3%● unchanged vs 05-2025
07-2025: 3.4%▲ +0.1 percentage points vs 06-2025
08-2025: 3.5%▲ +0.1 percentage points vs 07-2025
09-2025: 3.6%▲ +0.1 percentage points vs 08-2025highest value
10-2025: 0.6%▼ -3.0 percentage points vs 09-2025
11-2025: 0.6%● unchanged vs 10-2025
12-2025: 0.6%● unchanged vs 11-2025
01-2026: 0.6%● unchanged vs 12-2025
02-2026: 0.6%● unchanged vs 01-2026
03-2026: 0.6%● unchanged vs 02-2026
04-2026: 0.6%● unchanged vs 03-2026
05-2026: 0.6%● unchanged vs 04-2026
06-2026: 0.6%● unchanged vs 05-2026
07-2026: 0.3%▼ -0.3 percentage points vs 06-2026lowest value
08-2026: 0.3%● unchanged vs 07-2026lowest value
09-2026: 0.3%● unchanged vs 08-2026lowest value
10-2026: 0.3%● unchanged vs 09-2026lowest value
11-2026: 0.3%● unchanged vs 10-2026lowest value
Credit of up to €1,050,000 on 30-day terms is acceptable
Liquidity is tight, with a current ratio of 1.44 (1.06 in 2024), below the usual 1.5. Short-term debt is 12.8% and cash 3.7% of total assets. 12.8% of the assets are financed with debt and provisions.
Calculation
The band follows from the bankruptcy probability. 10 more points roughly halve it.
| 75-100 | Excellent | under 0.55% |
| 60-74 | Healthy | 0.55% to 1.5% |
| 45-59 | Fair | 1.5% to 4.2% |
| 25-44 | Weak | 4.2% to 15.0% |
| 0-24 | Critical | over 15.0% |
Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 46, small). It does better than 92% of them on solvency, 69% on liquidity, 13% on profitability and 68% on growth.
The bankruptcy probability was computed on 03-11-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.
Some facts cap the score, however low the probability. With negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late, the score is Fair at most (59). With two missing filings, it is Weak at most (44). During a judicial reorganisation or at the company's end (bankruptcy, dissolution, liquidation), it is Critical at most (24).
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
Five signals.
lowers riskraises riskneutral
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 11-06-2026, 50 days ahead of the deadline.
NBB · 10 filingsDeviation from the deadline
2025
50 days early
2024
46 days late
2023
54 days early
2022
56 days early
2021
61 days early
2020
67 days early
2019
61 days early
← before the deadline
after the deadline →
tick = median of all Belgian filingsring = median in the sector
The company filed its last 7 accounts on average 43 days before the deadline. In the sector (NACE 46), the median for financial year 2024 was 3 days before the deadline, and 39% of those companies filed late.
Searched, nothing found (2)
neutral · Next filing not due yet
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today. The company usually files around 8 June (4 of the last 5 accounts filed within 30 days either side of that date).
Companies Code · seven monthsWhere today falls in the filing period
04-11-2026 today31-12-2026 year end31-07-2027 deadline
Key points
- Risk: 5 loss-making years in a rowloss in financial year 2025 -€231,419 View
- Caution: Lower net result than 90% of companies in wholesale tradesector median €110,982 · 6,106 companies -€231,419 View
- Positive: Result rose in 2025from -€822,517 to -€231,419 ▲ 71.9% View
- A director leftlatest change 07-07-2026 · 3 in office 1 left View
Recent changes
- · Gazette deed Company renamed from PHARMA-PACK to Infinity PharmaResignation: VERLINDEN Johan (director)
- · Gazette deed Capital increase of €4,000,000 to €13,300,000
- · Gazette deed Appointment: PwC Bedrijfsrevisoren BV (statutory auditor)Permanent representative: Lien Winne
Companies linked to INFINITY PHARMA
Comparable companies
These companies have the same main activity as INFINITY PHARMA: wholesale of pharmaceutical and medical goods (NACE 46460). They are comparable in size and age: total assets between €7.3m and €14m, founded between 1970 and 1990.
| Company | Total assets | Turnover |
|---|---|---|
| INFINITY PHARMA Nazareth-De Pinte | €18.8m | €10.7m |
| VYGON Brussel | €14.3m | €8.5m |
| Ceres Pharmaceuticals Gent | €9.5m | €14.6m |
| BeMedico Herzele | €10.3m | €17.4m |
| STERIS Watermaal-Bosvoorde | €13.2m | €14.1m |
| S.A Therabel-Pharma N.V. Vorst | €12.8m | €15.7m |
| SOCIETE DISTRIBUTION MEDICALE Herstal | €7.3m | €10.0m |
Key facts about INFINITY PHARMA
- What is the company number of INFINITY PHARMA?
- The company number of INFINITY PHARMA is 0416.616.681. The VAT number is the same number with BE in front: BE 0416.616.681.
- Where is INFINITY PHARMA based?
- The registered office is at Venecoweg 20A, 9810 Nazareth-De Pinte.Company details
- What does INFINITY PHARMA do?
- According to the KBO register, the main activity is wholesale of pharmaceutical and medical goods (NACE 46460).
- What is the legal form of INFINITY PHARMA?
- The legal form of INFINITY PHARMA is Public limited company (NV).
- When was INFINITY PHARMA founded?
- INFINITY PHARMA was founded on 08-12-1976.
- Is INFINITY PHARMA still active?
- Yes, INFINITY PHARMA is an active enterprise in the KBO register.
- How many employees does INFINITY PHARMA have?
- INFINITY PHARMA had an average of 13.6 full-time equivalents in financial year 2025, according to the filed annual accounts.Financials
- Which joint committee does INFINITY PHARMA fall under?
- In its 2025 annual accounts, INFINITY PHARMA states joint committees 207 (Paritair Comité voor de bedienden uit de scheikundige nijverheid) and 116 (Paritair Comité voor de scheikundige nijverheid).
- What is the turnover of INFINITY PHARMA?
- The turnover of INFINITY PHARMA was €10.7m in financial year 2025, according to the filed annual accounts.
- Is INFINITY PHARMA profitable?
- In financial year 2025, INFINITY PHARMA made a loss of €231,419.
- Where can I find the annual accounts of INFINITY PHARMA?
- INFINITY PHARMA filed 49 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
- When are the next annual accounts of INFINITY PHARMA due?
- INFINITY PHARMA must file the annual accounts for financial year 2026 by 31-07-2027.Timeline
Next steps
Work out how much credit to give this customer and on what payment terms.Credit check Check what to know before you do business with this company.Supplier due diligence See whether the workforce is growing and whether people stay.Employer check Check whether you can accept this company as a client under the anti-money-laundering law.AML client file Check which of your other customers you can e-invoice via Peppol.Peppol check Compare this company with its sector.Sector benchmark
See how customers, suppliers and banks see your own company and what to improve first.